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Most of the drugs used in cancer chemo-
therapy affect the growth and metabolism of
not only malignant cells, but certain normal
tissues as well. In general, those tissues with
more rapid metabolic and mitotic rates such as
the bone marrow, gastro-intestinal epithelium,
and oral mueosa are most noticeably affected,
and damage to these tissues provides the most
common measurable signs of "toxicity" observed
during the administration of these agents.
The roots of growing human scalp hairs also
have a high metabolic and mitotic activity. The
germinative tissue of an average hair root, for
example, produces 0.35 mm. of hair shaft every
twenty-four hours (1), and in so doing, each day
approximately reduplicates its entire cell popu-
lation (2). It is not surprising therefore, that
these same anti-cancer agents may interfere
markedly with normal function of the hair root.
Damage to hair roots is not generally recog-
nized in patients unless the interference with
growth is severe enough to cause alopecia. Acute
hair loss can result only from a rather profound
disturbance of the growing hair root, since such
loss is the ultimate response in a series of graded
anatomical or biochemical alterations, each
proportionate to the degree of disturbance. Thus,
loss of hair following administration of Aminop-
term® has been reported to be correlated with
drug dosage (3), and anatomical alterations in
hair roots following Methotrexate® (10-methyl-
aminopterin) have been observed in the absence
of clinical alopecia (4).
Several points of interest arise from these
considerations. What agents cause identifiable
alterations in the hair root? Are the changes in
each instance similar or are there significant
differences? What are the conditions necessary
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for such damage? Of what practical value might
such information be, either in the clinical man-
agement of the patient or in assessment of drug
action?
The present study was undertaken to investi-
gate these questions by means of microscopic
examination of scalp hair roots epilated from
patients receiving a variety of ehemotherapeutic
agents, and comparing them with hairs from
patients receiving no drugs and from persons
without known illness. Changes in hairs, when
observed, were further compared with hemato-
logic alterations and other clinical signs secondary
to either drug or disease.
METHODS AND MATERIALS
For each examination, approximately one
hundred scalp hairs were manually epilated by
means of needle-holding forceps, one jaw of which
was coated with solder to assure a uniformly
tight closure of the jaws and prevent slip-
ping of the hairs grasped therein. The root
ends of the hairs were cut off with scissors,
evenly distributed in water in a small Petri dish
with a grid etched on the bottom surface, and
examined under a low-power (dissecting) micro-
scope.
Due to cyclically occurring periods of growth
and quiescence of hair, any large sampling of
hair from a given area may include both growing
(anagen) (Fig. 1A, 1B) and quiescent (telogen)
(Fig. 1C) types. In the human occipital scalp
approximately 86% of the hairs have been found
to be growing, the remainder quiescent (4). In
the present work, hairs were classified according
to the stage of the growth cycle in order to detect
possible variations from the normal ratio of
growing/resting, and in addition were examined
for the presence and structural variation of their
internal and external root sheaths, the appear-
ance of the germinative matrix of the hair bulb,
and the contour of the more distal keratogenous
zone and keratinized shaft.
As normal controls hairs were examined from
a group of 38 healthy persons which included
physicians, nurses, laboratory technicians and
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Fin. 1. Epilated normal scalp hair roots. A.
Growing (anagen) root with external sheath (I)
and internal sheath (II) intact. Keratogenous zone(III) appears dark in transmitted light. The mi-
totically active zone, the germinative matrix, is in
the lowermost portion of the root (IV). B. Appear-
ance of growing hair root in the absence of intact
internal and external root sheaths. The absence
of peribulbar sheaths permits the bulb to flare. C.
Resting (telogen) hair root. Such roots, the bulbs
of which are keratinized and mitotically inactive,
are not affected by drugs.
other hospital employees whose ages ranged
from 17—55 years. Hairs from the occipital scalp
were utilized in all cases; in 13 individuals hairs
were also obtained from the frontal and fronto-
parietal scalp areas for comparison to occipital
hairs.
Ninety-six patients,* whose ages ranged from
2—70 years, were included in this study. The
majority (92%) had a diagnosis of disseminated
cancer (including leukemia and lymphoma). The
diagnoses of the remainder included basal cell
carcinoma of the skin, psoriasis, rheumatoid
arthritis, gout, and congenital myxedema. Hair
samples were taken always from the occipital
scalp region of these patients. Control examina-
tions of hairs were done prior to the initiation of
* The bulk of the data of this paper was ob-
tained on patients of the several clinical services
of the National Cancer Institute. The authors
wish to express their thanks to the following physi-
cians for their cooperative assistance in making
this study possible; Dr. Paul Condit, Clinical
Pharmacology and Experimental TherapeuticsSection; Dr. Emil Frei and Dr. Emil J. Freireich,
Chemotherapy Service; Dr. Roy Hertz and Dr.
Delbert M. Bergenstal, Endocrinology Branch.
chemotherapy, and subsequent examinations
were made at repeated intervals after therapy
was begun. In 57 patients effects of the following
drugs were studied: methotrexate, 3' ,5' ,dichlo-
romethotrexatc, triethylene thiophosphoramide
(thio-tepa), 6-mercaptopurine, 5-fluorouracil,
colcemid, actinomycin D, mechlorcthamine
(nitrogen mustard), cyclophosphamide (Cy-
toxan®), and Vinca leukoblastin, a plant alkaloid
(5) presently undergoing preliminary clinical
trials (6). All drugs were administered thera-
peutically.
Changes in hairs were compared to changes in
peripheral white blood cell count, reticulocyte
count, platelet count, and other signs of toxicity
recorded by the physicians caring for the patients.
In order to establish unequivocal evidence of
drug effect on peripheral blood elements the
degree of alteration of these elements was calcu-
lated, and only the following changes were
accepted as significant.
1. A decrease in the number of circulating
white blood cells to a value of less than 45% of
the initial (pre-treatment) values, and to an
absolute level of less than 4000 cells per cu. mm.
2. A decrease in the number of circulating
platelets to less than 50% of the pre-treatment
level.
3. A ten-fold or greater decrease in the per-
centage of circulating reticulocytes.
It is recognized that these criteria are perhaps
somewhat rigid, but they were employed in order
to facilitate reliable correlation of hair changes
with definitive alterations of the formed elements
of the blood.
EE5ULT5
Scalp hairs in normal individuals. The per-
centage of growing hairs in the occipital scalp
of the 38 normal individuals was found to range
from 66—99%, with an average of 86.5%, values
which are in agreement with ones previously
reported (4). In some individuals the percentage
of growing hairs in other scalp regions was
markedly different from the occipital region, the
frontal and fronto-parietal areas generally having
lower percentages. This difference was greatest
in two men with advanced frontal balding, in
whom the frontal scalp was found to have re-
spectively 44% and 36% fewer growing hairs
than the occipital region. Increased numbers of
resting hairs also have been found in balding
scalps by histologic means (7). Some non-balding
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females in this study, however, also had de-
creased numbers of growing hairs in the anterior
scalp regions, though the differences were much
less.
The percentage of hairs epilated with the root
sheaths attached varied widely and did not
correlate with age or sex of the individuals. The
contour of the keratogenous zone was basically
similar in all individuals.
Scalp hairs in patients not receiving chemo-
therapy. The percentage of growing hairs in the
occipital scalp of persons with illnesses listed
above, and who were not receiving a cancer
ehemotherapeutie drug at the time, was found
to range from 35—100%, with an average of
85.5%. The range is greater than that found in
normal scalps, and is in agreement with pre-
viously published figures (4). Except for the
increased percentage of resting hairs in some of
these patients no other abnormality in hairs was
found, the structural appearance of the roots not
differing significantly from the normal.
The percentage of growing hairs from a single
examination was shown to be reliable when the
results of repeated examinations on a group of 53
patients not receiving chemotherapy were
analyzed. The average number of examinations
per patient was 6 (range of 2—33). The exami-
nations were repeated over periods of 1—30 weeks.
In only three of the 53 persons did the percentage
of growing hairs at any time deviate more than
10% from the mean in each ease. The average
deviation in all patients was
Changes in Hair Roots Following
Chemotherapeutic Drugs
Met hotrexate. Methotrexate, as all chemo-
therapeutic drugs, visibly affects growing (ana-
gen) hairs only, and not hairs in the quiescent
(telogen) stage of the growth cycle. The effect
of usual therapeutic doses of methotrexate on
the growing hairs of the scalp may be charac-
terized by an inhibition of growth of the hair
root, which is reversible when drug adminis-
Fm. 2. Appearance of epilated scalp hairs which show the effect of ehemotherapeutie drugs. A. Hair
root four days following the administration of methotrexate. The hair bulb and keratogenous zone are
diminished in diameter. B. Constiiction of the hair shaft 7 days following methotrexate administration.
Production of normal hair shaft proximal to constriction indicates that the germinative matrix (lower-
most) has recovered from the drug effect. C. Constriction in distal hair shaft indicative of methotrexate
therapy in the past. D. Hair shaft broken off at the point of severe constriction. E. Marked drug effect
with atrophy of the growing root. This hair will fall out but will be replaced by a new hair.
TABLE I
Comparative effects of Methotrexate on scalp hair, oral mucosa, and bone marrow
Patient
(1) H. R.
(2) J. S.
(3) I. L.
(4) R. R.
(5) 0. G.
(6) 0. FL
(7) 0. FL
(8) J. H.
(9) I. A.
(10) D. S.
(11) M. M.
(12) M. K.
(13) M. A.
(14) M. A.
(15) I. H.
(16) I. H.
(17) I. H.
(18) S. P.
(19) B. W.
(20) D. B.
(21) S. B.
(22) J. E.
(23) D. K.
(24) I. S.
(25) E. B.
(26) E. B.
(27) L. B.
Percentage of
Growing Hairs
Affected
0
100
100
0
0
0
0
0
72
100
100
98
85
79
100
100
100
100
100
100
100
100
63
100
97
100
91
Oral
Ulceration
0
+
0
+
0
+
0
0
+
+
+
+
+
0
+
+
+
+
+
+
+
+
+
+
+
+
+
Platelet
Decrease
0
+
+
+
0
+
+
+
0
+
+
+
0
0
+
+
+
+
+
+
+
+
+
+
0
0
0
Reticulocyte
Decrease
0
+
+
ND*
0
+
+
0
0
+
+
+
+
+
+
+
+
+
+
+
+
+
ND
+
0
+
+
WBC
Decrease
0
+
+
0
0
0
0
+
0
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
0
0
0
Dose of Methotrexate
2.5 mg/day
p.o. X 10
5.0 mg/day
p.o. X 3
5.0 mg./day
p.o. X 13
5.0 mg./day
p.o. X 53
7.5 mg/day
p.o. X 30
7.5 mg/day
p.o. X 15
7.5 mg/day
s.c. X 16
7.5 mg/day
p.o. X 17
10 mg/day
p.o. >< 6
10 mg/day
I.V. X 5
25 mg/day
IV. X 5
25 mg/day
IV. X 4
25 mg/day
I.V. X 5
25 mg/day
I.V. X 5
25 mg/day
I.V. X 5
25 mg/day
I.v. x 5
25 mg/day
I.v. x 5
25 mg/day
I.V. X 5
25 mg/day
I.V. X 5
25 mg/day
I.V. X 5
25 mg/day
IV. X 5
30 mg/day
IV. X 5
450 mg.
I.V. X 1
500 mg.
I.V. X 1
700 mg.
1V. x i
840 mg.
I.V. X 1
1000 mg.
I.V. X 1
* Not done.
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tration is discontinued (4). Four to six days
following a single adequate dose of the drug the
first change in the hair root recognized micro-
scopically is a diminution of the diameter of the
hair bulb and/or keratogenous zone (Fig. 2A).
As the hair root recovers from the insult growth
of the matrix resumes, and the shaft of the hair
produced within the next 2—5 days is found to
contain a segment with diminished diameter,
i.e. a constriction of the shaft (Figs. 2B, 2C).
(A twist in a hair that is oval in cross-section can
be distinguished from a constriction by rotating
the shaft with a fine forceps). The constriction
moves distally as the hair continues to grow,
moving progressively farther out from the hair
root. Breakage may occur at the point of a pro-
nounced constriction when the hair is pulled from
the scalp, and such broken hairs are recognized
microscopically by the tapering of the hair shaft
at the point of breakage (Fig. 2D).
Several patients in this study received similar
doses of methotrexate (25 mgm. intravenously
on four successive days) on two or more occasions
at approximately two-week intervals. Successive
constrictions of the hair shaft, corresponding to
the successive courses of drug, were demon-
strated, the distance between the constrictions
ill I I I I
— s—. Na White Blood CeIIs/cu.mm.Xl02
•———— NaP/ate lets /cu.mm. XI04
— s——. Percentage Reticulocytes Xl0'
• • Percentage of Hairs Affected
proportionate to the interval of time between
courses of drug.
Mention should be made of a particularly
marked effect of methotrexate on the hair roots
of one patient (Table I, Case # 2) in whom severe
toxicity developed in association with impaired
renal function. Total loss of scalp hair occurred,
and the hair bnlb portion of epilatcd hairs
appeared to have approached complete atrophy
(Fig. 2E). Regeneration of roots did occur, how-
ever, since rcgrowth of hair was clinically evident
within four weeks of hair loss.
Serial examinations of epilated scalp hairs
during and following 27 courses of mcthotrexate
therapy were performed on 22 patients and the
percentage of growing hairs showing the above
signs of damage from the drug was determined
in each instance. Evidence of drug effect on the
bone marrow, determined by definitive decreases
in the numbers of formed elements in the pe-
ripheral blood, was recorded. The presence of
ulceration of the oral mucous membrane, a
clinical sign of drug effect on normal tissue,
i.e., "toxicity" from the drug, was also noted.
Comparison of the data from these patients
(Table I) reveals that damage of scalp hair roots
is a sensitive indicator of toxic effects of metho-
trexate and may be as reliable as other more
I I I I I
— —. No. White Blood Cells/cu mm.X102
No.Plotelets /cu. mm. Xl04
— .——-. Percentage Reticulocytes X10'
. Percentage of Hairs Affected
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GRAPH II. Correlation of hair damage with
signs of toxicity following methotrexate. (Patient
I. A. #9, Table I.)
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GRAPH I. Correlation of hair damage with other
signs of toxicity following methotrexate. (Patient
M.A. #14, Table I.)
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TABLE II
Comparative effects of drugs other than Methotrexate on scalp hair, oral mucosa and bone marrow
commonly recognized signs. Each instance of
hair damage was accompanied by at least one
other sign of drug toxicity (see, for example,
Graph I). In seven instances hair changes oc-
curred in the absence of one or more of the usual
parameters of toxicity. For example, two patients(9, 25) with hair changes had no significant
alteration in the levels of circulating white blood
Patient
(1) S. S.
(1) C. R.
(2) W. J.
(3) E. D.
(4) N. N.
(5) J. J.
(6) M. W.
(7) I. S.
(1) R. T.
(2) C. B.
(3) C. B.
(4) 0. J.
(5) 0. J.
(6) D. S.
(7) B. D.
(1) M. H.
(2) V. C.
(3) V. A.
(4) W. G.
(1) I. F.
(1) S. K.
(2) S. K.
(1) M. A.
Agent
Dichloro-
methotrexate
5-fluorouracil
5-fluorouracil
5-fluorouracil
5-fluorouracil
5-fluorouracil
5-fluorouracil
5-fluorouracil
Actinomycin D
Aetinomycin D
Actinomycin D
Actinomycin D
Actinomycin 1)
Actinomycin D
Actinomycin D
Thio-tepa
Thio-tepa
Thio-tepa
Thio-tepa
Colcemid
Cytoxan
Cytoxan
Vinca Leuko-
blastin
Percentage
of Growing
Hairs
Aflected
100
0
0
99
0
0
90
100
85
0
0
0
0
100
100
0
0
0
100
100
0
100
100
Oral
Ulceration
0
0
0
0
0
0
+
+
0
+
0
0
0
+
+
0
0
0
+
+
0
0
+
Platelet
Decrease
+
0
0
+
0
0
0
+
0
+
+
0
+
+
+
0
0
0
+
+
0
0
+
Reticu-
locyte
Decrease
0
0
0
+
0
0
+
+
0
0
0
ND*
ND
+
+
0
0
0
+
+
0
+
+
WBC
Decrease
+
0
0
+
0
0
+
0
0
0
0
0
+
+
+
0
0
0
+
+
0
0
+
Dose
100 mg/day
I.M. X 4
3.4 mg./Kg./day
I.V. X 14
4 mg./Kg./day
IV. X 14
6 mg/Kg/day
I.V. X 8
6 mg/Kg/day
IV. X 14
6 mg./Kg./day
I.V. X 14
8 mg/Kg/day
I.V. X 8
15 mg./Kg./day
IV. X 5
20 sgm./Kg.
IV. X 1
50 ,gm./Kg.
IV. X 1
50 Mgm./Kg.
I.V. X 1
50 sgm./Kg.
IV. X 1
75 sgm./Kg.
IV. X 1
50 vgm./Kg.
IV. X 1
125 vsgm./Kg.
IV. X 1
0.2 mg/Kg/day
I.V. X 4
0.2 mg/Kg/day
I.V. X 4
0.2 mg/Kg/day
I.V. X 3
0.4 mg/Kg/day
I.V. X 4
5 mg/day
P.O. X 7
15 mg./Kg.
IV. X 1
20 mg/Kg.
IV. x 1
12 mg/day
IV. X 3
* Not done.
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cells, retieuloeytes, or platelets (Graph II). Hair
root changes were absent in four eases ( *4, * 6,
7, 8) having one or more signs of toxicity;
it is interesting that in these patients levels of
either reticulocytes or white blood cells were also
unchanged.
Dichiormethotrexate. Hairs were examined from
hut one patient following therapy with this
chlorinated derivative of methotrexate. Con-
strictions in the hair shafts indistinguishable
from those due to methotrexate were found
eoneommitantly with other signs of toxicity
(Table IT).
5-Fluorouracil. Seven patients receiving this
drug in varying dosage were observed. Hairs
from three of these showed signs of damage
indistinguishable from those due to methotrexate.
In each of these three individuals at least one
of the common signs of toxicity was absent. In
no ease was there clinical or hematologie effect
without recognizable hair changes.
Actinomycin D. Two of seven patients who
received this drug developed signs of severe
toxicity; in these two patients the matrix of all
growing hair roots appeared completely atrophic.
In another ease, constrictions of the hair shaft
like those following methotrexate were seen,
although this patient showed no hematologie
alterations. In three eases no hair changes were
demonstrated despite other evidence of toxicity.
Triethylene thiophosphoramide. (Thio-tepa).
One individual developed severe oral ulcerations
and depression of hematologie elements. The
roots of all growing scalp hairs appeared atro-
phied. Three other patients receiving smaller
doses of the drug had no evidence of toxicity.
Colcemid. Alopecia occurred in one patient who
received a total of 34 mgm. of eoleemid orally
over a period of seven days. Clinical and hemato-
logic signs of toxicity were correlated with
atrophy of the roots of all growing hairs. In one
other patient receiving eolcemid, in whom oral
ulcerations and depression of circulating white
blood cells developed, 22% of growing hairs were
found to be broken at the keratogenous zone
without evidence of constriction at this point.
Cyclophosphomide. (Cytoxan). One patient
was observed who received two successive single
intravenous doses of this drug, 15 and 20 mgm./
kgm. of body weight respectively. With the
smaller dose no clinical or hematologie signs of
toxicity occurred, nor did any changes in hair
roots. With the larger dose all growing hairs
showed focal constrictions, yet of the hemato-
logic elements only the retieulocyte count was
diminished.
Vinca leokoblastin. Therapy with this plant
alkaloid in one individual was followed by severe
toxicity in all parameters. Correspondingly, all
growing hair roots were atrophic. The atrophy
of the roots resulting from this drug, as when it
occurred in those instances following thio-tepa,
methotrexate, coleemid, and aetinomnyein D, was
followed by extensive alopeeia; regrowth of hair
within 4—6 weeks of hair loss was observed in all
cases.
Hair c/ian ges following other drugs. Varying
percentages (up to 22%) of hairs that were
broken off at the keratogenous zone, similar to
that seen in the one patient (above) following
eolcemid, were observed in several eases during
combined chemotherapy (simultaneous or se-
quential administration of small doses of two or
more chemotherapeutic agents). The same
phenomenon occurred in some patients receiving
nitrogen mustard or 6-mercaptopurine. How-
ever, no change of any kind appeared in hairs
from four patients who received nitrogen mustard
and in whom hematologic depression occurred
All of these patients had either leukemia or
Hodgkin's disease, and whether the hair changes,
when present, were associated with the drugs,
the specific disease, or unknown factors is not
apparent.
In no patient receiving any of the drugs in-
cluded in this study did the percentage of resting
hairs increase over pre-treatment values.
DISCUSSION
The variation in the percentages of growing
hairs from different areas of the scalp in an
individual, compared to the relatively constant
percentage of growing hairs in the occipital
scalp, emphasizes the need for using hairs from
one pre-selected areas in a study such as pre-
sented here.
Data derived from occipital hairs confirms the
observation that increased numbers of resting
hairs is associated with illness in some persons.
It seems important to re-emphasize also that
no increase in numbers of resting hairs was
observed following therapy with any of the
drugs. Since these drugs affect growing hairs
only, however, hairs lost as a consequence of
therapy are predominantly growing hairs; thus
the relatice percentage of resting hairs remaining
in the scalp rises. Hence, in the extreme circum-
stance of severe drug toxicity where all growing
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hairs are affected most scalp hair is lost. Because
the hairs remaining in the scalp must all be
resting, it is apparent that examination of the
patient at this time may lead to the erroneous
impression that the drug caused conversion of
hairs from the growing to the resting stage.
Although closer study, particularly with serial
histologic examinations of biopsy specimens of
scalp, might be expected to reveal that certain
anti-tumor drugs damage the hair root and
interfere with the growth of hair via mechanisms
that nrc characteristic for each drug or group of
drugs, no such differences could be ascertained
from microscopic examination of cpilatcd hairs.
The essential effect of each drug, whether alky-
lating agent, anti-mctabolite, or mitotic inhi-
bitor, seemed to be inhibition of growth of the
hair root that was promptly reversible when the
drug was discontinued. In those instances where
the insult was great enough to cause marked
atrophy of the hair bulb, precipitous loss of hair
occurred. Rcgrowth of hair was clinically visible
within 4—6 weeks.
While damage to hair following methotrexate
was associated with larger amounts of the drug
and with the appearance of clinical and hemato-
logic signs of toxicity, there was no linear cor-
relation of absolute dose administered with any
sign of drug toxicity. However, the most pro-
nounced hair root damage, marked atrophy,
invariably was associated with most severe
toxicity from methotrexate as measured by the
other signs. This correlation was also found with
other drugs.
Since the major route of excretion of metho-
trexate is renal (5), systemic accumulation of the
drug may result from impaired renal function,
and severe toxicity may occur following small
doses in patients with renal failure (5, 9). This
circumstance prevailed in patient J. S. (Table I,
2).
Clinically evident hair loss following drugs
may occur by two different mechanisms. Hairs
with atrophied roots are lost readily, either
falling out spontaneously or removed by such
casual procedures as combing the hair. Hairs
with marked constrictions of the shaft, on the
other hand, break off easily at the point of con-
striction. The root however remains in the
scalp, since it has already recovered from the
insult of drug and has produced the hair shaft
containing the constriction. Therefore, the
magnitude of damage to hair roots, and hence
degree of toxicity, cannot be ascertained from
the occurrence of hair loss alone but is best
determined from the microscopic appearance of
cpilated hairs.
The presence of definite signs of toxicity in
scalp hairs of patients who lack one or several of
the more commonly used signs of toxicity sug-
gests that the hair root is a rather sensitive
indicator of toxic effects of many cancer chcmo-
therapeutic drugs. Examination of epilated scalp
hairs can be of value in ascertaining the presence
or degree of toxicity in some patients receiving
these drugs.
SUMMARY
Structural damage of human scalp hairs occurs
following the administration of a variety of
cancer chcmotherapeutic drugs. A close cor-
relation is found between hair root damage and
hematologic signs of drug toxicity. The hair is a
sensitive indicator of the toxic effects of these
drugs. Examination of hair roots can be useful
in the clinical management of patients receiving
chemotherapeutic drugs.
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